Osteosarcoma
Osteosarcoma refers to a malignant connective tissue tumor in which tumor cells can directly produce tumor bone and bone-like tissue. Its incidence ranks first among primary malignant tumors. The tumor is highly malignant and has extremely poor prognosis. It can metastasize to the lungs within a few months, and the survival rate is only 5% to 20% 3 to 5 years after amputation. About three-quarters of all osteosarcomas occur in the lower end of the femur and the upper end of the tibia, and can also occur in other places such as the humerus, upper end of the femur, fibula, spine, ilium, etc. Most are osteolytic, and a few are osteoblastic. Age of onset: It can occur at any age, but mostly between 10 and 25 years old, and more often in men. The tumor is mostly at the end of the bone, and occasionally occurs in the backbone or epiphysis.
-
Site of disease:
bone -
Infectious :
Not contagious -
Frequent population:
All people, often in adolescents -
Related symptoms:
Severe pain Lung metastasis Knee pain Dyspnea Recurrent fractures in children -
Concurrent disease:
Related Drugs
METHOTREXATE- methotrexate_injection, solution
Indication: Methotrexate Injection is a dihydrofolate reductase inhibitor indicated for the treatment of: adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen ( 1. 1 adults with relapsed or refractory non-Hodgkin lymphoma as part of a combination chemotherapy regimen ( 1. 2 adults and pediatric patients with Burkitt lymphoma as part of a combination chemotherapy regimen ( 1. 3 adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen ( 1. 4 Limitations of Use: 1. 5 Methotrexate Injection is indicated for the treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen. Methotrexate Injection is indicated for the treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a combination chemotherapy regimen. Methotrexate Injection is indicated for the treatment of adults and pediatric patients with Burkitt lymphoma as part of a combination chemotherapy regimen. Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. Methotrexate Injection is not indicated for non-oncology diseases.
Manufacturer:
Accord Healthcare Inc.
METHOTREXATE_- methotrexate_injection, solution
Indication: Methotrexate Injection is a folate analog metabolic inhibitor indicated for: The following neoplastic diseases for the: 1. 7 Treatment of adults with rheumatoid arthritis (RA). 8 Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). 9 Treatment of adults with severe psoriasis. 10 Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen. Methotrexate Injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients. Methotrexate Injection is indicated for the treatment of adults and pediatric patients with Non-Hodgkin lymphoma. Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. Methotrexate Injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy regimen. Methotrexate Injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a single-agent. Methotrexate Injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (GTN) as part of a combination chemotherapy regimen. Methotrexate Injection is indicated for the treatment of adults with rheumatoid arthritis (RA). Methotrexate Injection is indicated for the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis (pJIA). Methotrexate Injection is indicated for the treatment of adults with severe psoriasis.
Manufacturer:
Eugia US LLC
METHOTREXATE- methotrexate_injection, solution
Indication: Methotrexate Injection is a folate analog metabolic inhibitor indicated for: o 1. 10 Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen. Methotrexate Injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients. Methotrexate Injection is indicated for the treatment of adults and pediatric patients with non-Hodgkin lymphoma. Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. Methotrexate Injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy regimen. Methotrexate Injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a single agent. Methotrexate Injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (GTN) as part of a combination chemotherapy regimen. Methotrexate Injection is indicated for the treatment of adults with rheumatoid arthritis (RA). Methotrexate Injection is indicated for the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis (pJIA). Methotrexate Injection is indicated for the treatment of adults with severe psoriasis.
Manufacturer:
Hospira, Inc.